Köpeklerde Karaciğer Hasarı ve MikroRNA-122

Yıl 2021, , 223 - 228, 20.08.2021

Aliye Sağkan Öztürk

https://doi.org/10.53493/avrasyasbd.872174

Öz

Genom tarafından kodlanan tek iplikli RNA molekülü olan ve biyolojik süreçlerde rol oynayan mikroRNA'lar, pek çok dokuda ifade edilmekte ve serum düzeyleri doku hasarı hakkında bilgi sağlamaktadır. Bunlardan biri olan miR-122, insanlarda karaciğer hasarından sonra kanda belirlenebilen doğrulanmış bir biyobelirteçtir. İnsanlarda olduğu gibi köpeklerde de klasik karaciğer fonksiyon testleri (aminotransferazlar) özellikle kronik karaciğer hasarını ortaya koymada yetersiz olabilmektedir. Bundan dolayı karaciğer hasarının özellikle ileri ve klinik bulgu göstermeyen dönemde ortaya konulmasında miR-122'nin etkinliği ve bazı köpek karaciğer hastalıklarında yapılan çalışmalar hakkında bilgi veren bu derlemede miR-122'nin güvenilir bir biyobelirteç olarak kullanılabileceği sonucuna varılmıştır.

Anahtar Kelimeler

miR-122, köpek, karaciğer hasarı

Destekleyen Kurum

Yok

Proje Numarası

Yok

Teşekkür

Yok

Kaynakça

• Ambros V. (2004). The functions of animal microRNAs. Nature, 431(7006):350–5.
• Ardekani AM & Naeini MM. (2010). The Role of MicroRNAs in Human Diseases. Avicenna journal of medical biotechnology, 2(4):161–179.
• Arroyo JD, Chevillet JR, Kroh EM, et al. (2011). Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc. Natl. Acad. Sci. USA, 108:5003–5008.
• Castoldi M, Vujic Spasic M, Altamura S, et al. (2011). The liver-specific microRNA miR-122 controls systemic iron homeostasis in mice. The Journal of Clinical Investigation, 121:1386-1396.
• Cortez MA, Bueso-Ramos C, Ferdin J, et al. (2011). MicroRNAs in body fluids—The mix of hormones and biomarkers. Nat. Rev. Clin. Oncol, 8:467–477.
• Dirksen K, Burgener IA, Rothuizen J, et al. (2017). Sensitivity and specificity of plasma ALT, ALP, and bile acids for hepatitis in Labrador Retrievers. J Vet Intern Med, 31:1017-1027.
• Dirksen K, Verzijl T, Grinwis GC, et al. (2016A). Use of serum microRNAs as biomarker for hepatobiliary diseases in dogs. J Vet Intern Med, 30:1816-1823.
• Dirksen K, Verzijl T, van den Ingh TS, et al. (2016B). Hepatocyte-derived microRNAs as sensitive serum biomarkers of hepatocellular injury in Labrador retrievers. Vet J, 211:75-81.
• El-Sebaey AM, Abramov PN, Borunova SM, (2020A) Cfa-miRNAs 122 and –21 as modern biomarkers of primary hepatitis in dogs. RUDN Journal of Agronomy and Animal Industries, 15(3):294-307.
• El-Sebaey AM, Abramov PN, Abdelhamid FM, (2020B). Clinical Characteristics, Serum Biochemical Changes, and Expression Profile of Serum Cfa-miRNAs in Dogs Confirmed to Have Congenital Portosystemic Shunts Accompanied by Liver Pathologies. Vet Sci, 25:7(2):35.
• Eman SR, Kubesy AA, Baraka TA, et al. (2018). Evaluation of hepatocyte-derived microRNA-122 for diagnosis of acute and chronic hepatitis of dogs. Vet World, 11(5):667-673.
• Favier RP. (2009). Idiopathic hepatitis and cirrhosis in dogs. Veterinary Clinics of North America: Small Animal Practice, 39:481-488.
• Gebert LFR, MacRae IJ. (2019). Regulation of microRNA function in animals. Nat Rev Mol Cell Biol, 20(1):21-37.
• Hayes CN, Chayama K, (2016). MicroRNAs as biomarkers for liver disease and hepatocellular carcinoma. Int J Mol Sci, 17:280.
• Koenig EM, Fisher C, Bernard H, et al. (2016). The beagle dog MicroRNA tissue atlas: identifying translatable biomarkers of organ toxicity. BMC Genomics, 17:649.
• Lai YC, Ushio N, Rahman MM, et al. (2018). Aberrant expression of microRNAs and the miR-1/MET pathway in canine hepatocellular carcinoma. Vet Comp Oncol, 16(2):288-296.
• Landgraf P, R usu M, Sheridan R, et al. (2007). A mammalian microRNA expression atlas based on small RNA library sequencing. Cell, 129:1401-1414.
• Lawrie CH, Gal S, Dunlop HM, et al. (2008). Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br. J. Haematol, 141:672–675.
• Lidbury JA, Suchodolski JS, (2016). New advances in the diagnosis of canine and feline liver and pancreatic disease. Vet J, 215:87-95.
• Novellino L, Rossi RL, Bonino F, et al. (2012). Circulating hepatitis b surface antigen particles carry hepatocellular microRNAs. PLoS ONE, 7:e31952.
• O'Brien A, Zhou T, Tan C, et al. (2019). Role of Non-Coding RNAs in the Progression of Liver Cancer: Evidence from Experimental Models. Cancers, 11(11): 1652.
• Oosthuyzen W, Ten Berg PWL, Francis B, et al. (2018). Sensitivity and specificity of microRNA-122 for liver disease in dogs. J Vet Intern Med, 32(5):1637-1644.
• Poldervaart JH, Favier RP, Penning LC, et al. (2009). Primary hepatitis in dogs: a retrospective review (2002–2006). J Vet Intern Med, 23:72-80.
• Ramadan ES, Kubesy AA, Baraka TA, et al. (2019). Expression of blood hepatocyte-derived microRNA-122 in canine multicentric lymphoma with hepatic involvement. Vet Res Commun, 43(4):231-238.
• Saini HK, Griffiths-Jones S, Enright AJ. (2007). Genomic analysis of human microRNA transcripts. Proc Natl Acad Sci U S A, 6;104(45):17719-24.
• Sakai M, Spee B, Grinwis GCM, et al. (2019). Association of circulating microRNA-122 and microRNA-29a with stage of fibrosis and progression of chronic hepatitis in Labrador Retrievers. J Vet Intern Med, 33(1):151-157.
• Shih JL, Keating JH, Freeman LM, et al. (2007). Chronic hepatitis in Labrador Retrievers: clinical presentation and prognostic factors. J Vet Intern Med, 21:33-39.
• Shwetha S, Gouthamchandra K, Chandra M, et al. (2013). Circulating miRNA profile in HCV infected serum: Novel insight into pathogenesis. Sci. Rep, 3:1555.
• Starckx S, Batheja A, Verheyen GR, et al. (2013). Evaluation of miR-122 and other biomarkers in distinct acute liver injury in rats. Toxicol Pathol, 41(5):795–804.
• Westholm JO, Lai EC. (2011). Mirtrons: microRNA biogenesis via splicing. Biochimie, 93(11):1897-904.